|
|
 |
|
Viewing report
|
|
|
|
Partnering Agreements with BigPharma
CurrentPartnering, Feb 2012, Pages: 712
The Partnering Agreements with Bigpharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.
This premier report provides all the information you require to better understand bigpharma partnering.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.
This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and dealmaking activity since 2007.
Chapter 3 reviews the top deals of 2007-2011 according to reported deal size.
Chapter 4 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.
Chapter 5 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.
The main body of the report is provided in chapter 6. In-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.
Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.
Key benefits
Partnering Agreements with Bigpharma provides the user with the following key benefits:
- Detailed partnering activity profiles for each of the top 50 bigpharma companies
- Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners
- Partnering therapy focus revealed
- Partnering activity since 2007 – number of deals per year
- Full listing of partnering deals
- Activity by deal type
- Activity by industry sector
- Activity by phase of development
- Activity by technology type
- Activity by therapeutic area
- Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
- Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Partnering Agreements with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s partnering.
Partnering Agreements with Bigpharma includes:
- Detailed company profiles for each of the top 50 bigpharma companies, including:
- Partnering interests and indications
- Partnering activity since 2007
- Partner companies since 2007
- Partnering activity since 2007 by:
- Partner company
- Deal type
- Industry sector
- Stage of development
- Technology type
- Therapy area
- Over 300 charts showing the dealmaking activity of each company since 2007
- The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
- 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
- The leading M&A and partnering deals by value 2007-2012
The Partnering Agreements with Bigpharma report also provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Partnering Agreements with Bigpharma provides the user with the following key benefits:
- Detailed partnering activity profiles for each of the top 50 bigpharma companies
- Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners
- Partnering therapy focus revealed
- Partnering activity since 2007 – number of deals per year
- Full listing of partnering deals
- Activity by deal type
- Activity by industry sector
- Activity by phase of development
- Activity by technology type
- Activity by therapeutic area
- Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
- Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Oncology Partnering Terms and Agreements
Personalized Medicine Partnering Terms and Agreements
Vaccine Partnering Terms and Agreements
Cardiovascular Partnering Terms and Agreements
Antibody Partnering Terms and Agreements
Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 5th edition
Drug Delivery Partnering Terms and Agreements in Pharma and Biotech 2nd Edition
Biomarker Partnering Terms and Agreements
Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition
Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition
|
|
|
|
